By clicking "Allow," you will be taken to a website that is independent of ViiV Healthcare. The site you linking to is not controlled or endorsed by ViiV Healthcare, and ViiV Healthcare is not responsible for the content provided on that site.
This site is intended for US healthcare professionals only.
Real-world adherence and persistence with long-acting cabotegravir plus rilpivirine (CAB+RPV LA) compared to oral antiretroviral therapy (ART) among people with HIV (PWH) in the US: the ABOVE study
Real-world adherence and persistence with long-acting cabotegravir plus rilpivirine (CAB+RPV LA) compared to oral antiretroviral therapy (ART) among people with HIV (PWH) in the US: the ABOVE study
Perspectives of people with HIV (PWH) 6 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND)
Perspectives of people with HIV (PWH) 6 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND)
Video Player is loading.
Current Time 0:00
/
Duration 4:28
Loaded: 2.22%
0:00
Stream Type LIVE
Remaining Time -4:28
1x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
en (Main), selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Healthcare staff perceptions of feasibility and acceptability on implementing injectable HIV pre-exposure prophylaxis into standard of care: baseline results from the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)
Healthcare staff perceptions of feasibility and acceptability on implementing injectable HIV pre-exposure prophylaxis into standard of care: baseline results from the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)
Video Player is loading.
Current Time 0:00
/
Duration 4:30
Loaded: 2.20%
0:00
Stream Type LIVE
Remaining Time -4:30
1x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
en (Main), selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Engaging black women on cabotegravir LA for PrEP by optimizing novel implementation strategies (EBONI) study: provider perceptions of appropriateness cabotegravir LA for PrEP for cis- and- trans black women
Engaging black women on cabotegravir LA for PrEP by optimizing novel implementation strategies (EBONI) study: provider perceptions of appropriateness cabotegravir LA for PrEP for cis- and- trans black women
Video Player is loading.
Current Time 0:00
/
Duration 4:32
Loaded: 2.18%
0:00
Stream Type LIVE
Remaining Time -4:32
1x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
en (Main), selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Integrating long-acting injectable cabotegravir for PrEP into standard of care for cisgender women, transgender women, transgender men, and men who have sex with men: results from the PILLAR & EBONI studies
Integrating long-acting injectable cabotegravir for PrEP into standard of care for cisgender women, transgender women, transgender men, and men who have sex with men: results from the PILLAR & EBONI studies
Video Player is loading.
Current Time 0:00
/
Duration 5:05
Loaded: 1.95%
0:00
Stream Type LIVE
Remaining Time -5:05
1x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
en (Main), selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Virological Suppression in People with HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar across Age Groups despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis)
Virological Suppression in People with HIV-1 (PWH) Receiving Dolutegravir/Lamivudine Was High and Similar across Age Groups despite Older PWH Having Increased Rates of Comorbidities and Polypharmacy (TANDEM Subgroup Analysis)
Video Player is loading.
Current Time 0:00
/
Duration 3:33
Loaded: 2.79%
0:00
Stream Type LIVE
Remaining Time -3:33
1x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
en (Main), selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Durable efficacy and robust CD4+ T-Cell count improvement observed among age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
Durable efficacy and robust CD4+ T-Cell count improvement observed among age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment
Video Player is loading.
Current Time 0:00
/
Duration 4:03
Loaded: 2.44%
0:00
Stream Type LIVE
Remaining Time -4:03
1x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
en (Main), selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.
Are you a US healthcare provider?
This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch
This site uses cookies and similar technologies (collectively, "cookies") to enhance your website experience and track the site's performance. These cookies are automatically enabled. By using this site, you agree to our use of these cookies in accordance with our Privacy Notice. Click on Privacy Choices below to manage your preferences, including to opt out of the sale or sharing of your information.
Managing Privacy Options
OPT OUT OF SALE AND SHARING OF INFORMATION
Your state law may allow you the right to opt out of the sale or sharing of your personal information for targeted advertising. You may opt out of such sale or share via the toggle available to you for "Targeting Cookies," and selecting the "Confirm my choices” button below. To limit sale or sharing of your information for targeting advertising offline, please see the "Cookies and Targeted Advertising Choices," section in the Privacy Notice and submit the required form.
Always Active
Necessary for the website to function appropriately, such as to store session data during a website visit, to manage cookie and tag preferences, and to protect the security of the website. In addition, some of these cookies are set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms.
Always Active
Enable the website to provide enhanced functionality and personalization, such as by helping us to measure how many visitors come to our websites, what sites our website visitors come from, and how often certain pages on our website are viewed. These cookies may be set by us or by third party providers, like our analytics service providers, whose services we have added to our pages.
Allow us to target and re-target you with relevant advertising. We and our advertising partners use information collected through these technologies to infer your interests in order to serve you more relevant advertisements on other sites. If you don’t allow these cookies, you will receive advertising, but it may be less relevant to you.
